
“That constellation of features raises questions about what would happen and what could be done about it,” says Jeffrey Kahn, director of the Johns Hopkins Berman Institute of Bioethics
Quick Read“That constellation of features raises questions about what would happen and what could be done about it,” says Jeffrey Kahn, director of the Johns Hopkins Berman Institute of Bioethics
Quick Read
Scientists Repair Disease-Causing Gene in Human EmbryosAugust 2, 2017 |
“This is very elegant lab work,” but it’s moving so fast that society needs to catch up and debate how far it should go, said Johns Hopkins University bioethicist Jeffrey Kahn. And lots more research is needed to tell if it’s really safe, added Britain’s Lovell-Badge
Quick Read
The First US Team to Gene-Edit Human Embryos RevealedJuly 28, 2017 |
If a peer-reviewed paper bears out the news story, “It’s one more step on the path to potential clinical application,” says bioethicist Jeffrey Kahn of Johns Hopkins Berman Institute of Bioethics, who served on a committee convened by the NASEM to address gene editing. The panel’s report earlier this year concluded that a clinical trial involving embryo editing would be ethically allowable under narrow circumstances.
Quick Read
Safe and Ethical Ways to Edit the Human GenomeFebruary 27, 2017 |
The National Academies of Science and Medicine (NASEM) released a report on Feb. 14 exploring the implications of new technologies that can alter the genome of living organisms, including humans
Quick Read
Gene-Editing Gets A Go-AheadFebruary 22, 2017 |
Those in the know call CRISPR “one of the greatest life science inventions ever.” It has revolutionized the ability to make precise changes to human DNA, opening the door to revolutionary ways to treat disease – but also to ethical questions about engineered designer babies. This hour On Point, the brave new world of human DNA editing and CRISPR. Guests include our Jeffrey Kahn
Quick Read
Human Gene Editing Therapies Are OK in Certain Cases, Panel AdvisesFebruary 15, 2017 |
Expert group recommends long-term tracking, other restrictions for germline tinkering. Jeffrey Kahn, a bioethicist at Johns Hopkins University, says the door to heritable gene therapy remains closed until stringent requirements can be met. “It’s frankly more of a knock on the door,” he said at the public presentation of the report
Quick Read
Reconsidering Research on PrimatesDecember 5, 2016 |
Jeffrey Kahn, a Johns Hopkins bioethicist who chaired the Institute of Medicine’s chimpanzee review, floated the possibility of a similar review for other primate research. Responding to a comment about the necessity of that research, Kahn noted that similar claims had been made about chimp experiments
Quick Read
Hopkins Bioethics Scholar Elected to NAMOctober 17, 2016 |
Jeffrey P. Kahn, Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics, has been elected to the National Academy of Medicine (NAM).
Read More